Becoming educated and informed about Alzheimer’s is a good first step. Here you’ll find general information about the disease, including diagnosis, symptoms, and causes.

Alzheimer’s in people younger than 65 linked to night light exposure. Higher exposure to outdoor light at night may increase the risk of developing Alzheimer’s disease, especially in people younger than 65, according to a study that drew on Medicare records and …

2023年9月22日 · ALZ-801 aims to work as a preventive therapy in early Alzheimer’s. Alzheimer’s is marked by the presence of beta-amyloid plaques and tau tangles, which are clumps of two proteins that build up to toxic levels inside brain nerve cells.

2025年2月7日 · The U.S. Food and Drug Administration (FDA) has approved monthly maintenance dosing for Leqembi (lecanemab), a treatment for early Alzheimer’s disease.

Alzheimer’s News Today is a digital platform intended to provide the Alzheimer’s disease community with the most recent news and information on the disease, as well as first-hand community perspectives from our patient and caregiver columnists.

Publishing the web’s most comprehensive platform for Alzheimer’s News, columns, patient perspectives and resources requires a significant investment of resources each month for our talented and growing staff of PhD researchers, veteran journalists, talented social media team, and patient columnists.

2023年7月11日 · The Phase 2/3 DIAN-TU trial (NCT05269394) is investigating the safety and efficacy of Leqembi in combination with an anti-tau antibody (E2814) as a potential treatment for Alzheimer’s. Tau is another protein that builds up to toxic levels in people with Alzheimer’s.

2024年12月6日 · Muna will take the lead in identifying and validating new Alzheimer’s targets, while GSK will be responsible for the subsequent therapeutic development process, including preclinical studies, clinical trials, manufacturing, and commercialization, the companies said.

2021年6月25日 · Alzheimer’s disease is a progressive neurodegenerative disorder and the most common cause of dementia. It most often emerges during a person’s mid-60s or older, although early-onset varieties exist.

2025年1月3日 · In clinician-rated measures, significantly fewer patients given AXS-05 than a placebo had a worsening of agitation (20.5% vs. 41.7%) or a worsening of overall Alzheimer’s severity (13.3% vs. 39.3%).